London, United Kingdom

Christopher James Wheelhouse



Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christopher James Wheelhouse: Innovator in Hepatitis C Treatment

Introduction

Christopher James Wheelhouse is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hepatitis C. His innovative work has led to the development of a unique compound that holds promise for patients suffering from this viral infection.

Latest Patents

Christopher holds a patent for "Biphenyl derivatives and their use in treating hepatitis C." This patent describes the use of a compound that is a biphenyl derivative of formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of hepatitis C. The variables and specific applications of this compound are detailed within the patent documentation. He has 1 patent to his name, showcasing his inventive capabilities.

Career Highlights

Throughout his career, Christopher has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with AstraZeneca and Arrow Therapeutics Limited. His experience in these organizations has allowed him to contribute to significant advancements in drug development and therapeutic solutions.

Collaborations

Christopher has collaborated with esteemed colleagues, including Alexander James Floyd Thomas and David John Bushnell. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Christopher James Wheelhouse is a distinguished inventor whose work in developing biphenyl derivatives for hepatitis C treatment exemplifies his commitment to advancing medical science. His contributions to the pharmaceutical industry continue to impact the lives of many patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…